ARCHIVES

Phase II Elotuzumab Study Demonstrates 33 Months PFS

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Mozobil Plus G-CSF Increases Rate Of Cell Mobilization

September 30, 2005

Cancer Center Planning Grants Recompetition Approved By Advisors

June 10, 1994

Duke Scores Highest On NCAB Review

July 14, 1978

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

October 26, 2012

PLCO Data Confirm Importance Of Regular Colorectal Cancer Screening, NCI Says

July 25, 2003

NCI-Approved Clinical Trials For The Month of June

June 24, 2011